Shionogi: Bacterial Infections trials

The registry lists 11 Bacterial Infections studies with Shionogi as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 9Phase 2 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal ImpairmentCompletedNCT07104162Phase 1
• A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult ParticipantsCompletedNCT06547554Phase 1
• PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal ImpairmentCompletedNCT06157242Phase 1
• P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy ParticipantsCompletedNCT06079775Phase 1
• Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult SubjectsCompletedNCT05072444Phase 1
• SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy VolunteersCompletedNCT04808414Phase 1
• Phase 1 Oral QPX7831 SAD and MAD in Healthy AdultsCompletedNCT04578873Phase 1
• P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHVCompletedNCT04380207Phase 1
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric ParticipantsCompletedNCT04215991Phase 2
• Phase 1 Study of Oral QPX2015 in Healthy Adult SubjectsCompletedNCT03939429Phase 1
• Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial InfectionsApproved for marketingNCT03780140